Aducanumab failed in efficacy. They reworked the d
Post# of 150221
(Total Views: 647)
Posted On: 02/06/2021 4:47:32 PM
Aducanumab failed in efficacy. They reworked the data and low and behold 30% of the patients showed slowed progression of the disease. The FDA does not like datamined BLAs. There's also no getting around the up to 50% of patients developing micro-hemorrhaging in the brain.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼